Stock-based Compensation - Narrative (Details) $ / shares in Units, $ in Thousands				1 Months Ended	12 Months Ended
	Jan. 01, 2025 shares	Dec. 31, 2024 shares	Nov. 16, 2023 USD ($) grantee $ / shares shares	Jun. 30, 2021	Dec. 31, 2025 USD ($) $ / shares shares	Dec. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation cost related to unvested awards not yet recognized | $					$ 26,600
Expected weighted-average period compensation cost to be recognized (in years)					2 years 4 months 24 days
Clinical development milestones, probable achievement (in shares) | shares					58,238
Total stock-based compensation expense | $					$ 41,829	$ 33,144	$ 47,084
Weighted average grant date fair value (in dollars per share) | $ / shares					$ 10.31	$ 26.00	$ 33.80
Intrinsic value of options exercised | $					$ 100	$ 2,900	$ 6,500
ICT License Acquisition
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Asset acquisition, contingent consideration probable achievement, share-based compensation expense | $					19,700
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense | $					$ 28,743	$ 14,577	18,207
Stock option | 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Minimum exercise price of plan modifications (in dollars per share) | $ / shares			$ 47.40
Original exercise price lower range (in dollars per share) | $ / shares			52.20
Original exercise price upper range (in dollars per share) | $ / shares			$ 359.00
Share-based payment arrangement, plan modification, number of grantees affected | grantee			200
Shares repriced (in shares) | shares			1,170,843
Plan modification, exercise price (in dollars per share) | $ / shares			$ 37.40
Incremental stock-based compensation expense of modifications | $			$ 8,900
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards outstanding (in shares) | shares		281,190			306,415	281,190
Fair value of awards vested during period | $					$ 1,700	$ 2,000	1,400
Performance-Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award expiration period (in years)					10 years
Award performance period (in years)					3 years
Clinical development milestones, probable achievement (in shares) | shares					7,062
Performance-Based Stock Options | Share-Based Payment Arrangement, Tranche One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting rights, percentage					50.00%
Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award performance period (in years)					3 years	3 years
Service period from the milestone achievement date (in years)					1 year
Total stock-based compensation expense | $					$ 1,700	$ 1,900	0
Awards outstanding (in shares) | shares		135,170			65,518	135,170
Fair value of awards vested during period | $					$ 400	$ 0	$ 0
Maximum | Performance-Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance period relative to total shareholder return (in years)					3 years
Awards granted, percentage of target					200.00%
Maximum | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance period relative to total shareholder return (in years)						3 years
Minimum | Performance-Based Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance period relative to total shareholder return (in years)					2 years
Awards granted, percentage of target					0.00%
Minimum | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance period relative to total shareholder return (in years)						2 years
2021 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award expiration period (in years)				10 years
Proportion of stock outstanding (as a percent)		5.00%
Number of additional shares authorized for issuance (in shares) | shares	737,188
Vesting period (in years)				4 years
Future issuance of common shares (in shares) | shares					2,105,974
2021 Plan | Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award performance period (in years)				3 years
2021 ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Future issuance of common shares (in shares) | shares					200,833
Purchase of common stock at discount (as a percent)				15.00%
Purchase price in relation to common stock price (as a percent)				85.00%
Awards issued during period (in shares) | shares					51,799	47,738	49,320